Literature DB >> 2432192

Neuronal RNA in relation to neuronal loss and neurofibrillary pathology in the hippocampus in Alzheimer's disease.

J A Doebler, W R Markesbery, A Anthony, R E Rhoads.   

Abstract

Topographic analyses were performed on the distribution of neuronal RNA loss in relation to local neuronal loss and neurofibrillary degeneration in the hippocampal region of brains of patients with Alzheimer's disease (AD). Compared to age-matched controls, pyramidal neuronal RNA was depressed (p less than 0.0001) in all areas of the hippocampus examined in AD, viz., the endplate (33%), Rose's H2 field (30%), Rose's H1 field (37%) and the subiculum (46%). Significant neuronal loss was observed in Rose's H1 field and the subiculum but not in the endplate or Rose's H2 field. The frequency of neurofibrillary tangle-bearing neurons was enhanced in all four regions of AD brains, the number of involved neurons being markedly greater in Rose's H1 field and the subiculum than in the endplate and Rose's H2 field. Overall, the data indicate the existence of a generalized disturbance in RNA metabolism within pyramidal neurons in the hippocampus in AD, occurring in regions of minimal (endplate, Rose's H2 field) as well as those of extensive (Rose's H1 field, subiculum) pathological alterations. Although there is focal accentuation of RNA depletion in the latter, the marked RNA depletion in regions of minimal pathologic change suggests that this effect is largely unrelated to local neuronal loss or neurofibrillary degeneration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432192     DOI: 10.1097/00005072-198701000-00003

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  9 in total

1.  Aluminum, altered transcription, and the pathogenesis of Alzheimer's disease.

Authors:  D R Crapper McLachlan; W J Lukiw; T P Kruck
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

Review 2.  Alzheimer's disease--neuropathological aspects.

Authors:  C Bergeron
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

Review 3.  Diagnostic confirmation, severity, and subtypes of Alzheimer's disease. A short review on clinico-pathological correlations.

Authors:  H Förstl; P Fischer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

4.  The effect of age and Alzheimer's disease on pyramidal neuron density in the individual fields of the hippocampal formation.

Authors:  D C Davies; N Horwood; S L Isaacs; D M Mann
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

5.  Astrocyte RNA in relation to neuronal RNA depletion in Alzheimer's disease.

Authors:  J A Doebler; W R Markesbery; A Anthony; S W Scheff; R E Rhoads
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer disease.

Authors:  W S Griffin; C Ling; C L White; M Morrison-Bogorad
Journal:  Alzheimer Dis Assoc Disord       Date:  1990       Impact factor: 2.703

Review 7.  Tau-mediated dysregulation of RNA: Evidence for a common molecular mechanism of toxicity in frontotemporal dementia and other tauopathies.

Authors:  Shon A Koren; Sara Galvis-Escobar; Jose F Abisambra
Journal:  Neurobiol Dis       Date:  2020-05-12       Impact factor: 5.996

8.  Sub-Regional Hippocampal Injury is Associated with Fornix Degeneration in Alzheimer's Disease.

Authors:  Dong Young Lee; Evan Fletcher; Owen Thomas Carmichael; Baljeet Singh; Dan Mungas; Bruce Reed; Oliver Martinez; Michael H Buonocore; Maria Persianinova; Charles Decarli
Journal:  Front Aging Neurosci       Date:  2012-04-11       Impact factor: 5.750

9.  Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus.

Authors:  Karan Govindpani; Clinton Turner; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.